SCHEMBL5458362

SCHEMBL5458362

COc1ccccc1NC(=O)Nc1ccc(C2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.58
NPC1 O15118 7/20 0.58
MAPT P10636 5/20 0.58
SMN1; SMN2 Q16637 4/20 0.57
L3MBTL1 Q9Y468 1/20 0.54
TP53 P04637 2/20 0.53
ALOX15 P16050 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ACHE P22303 1/20 0.51
BACE1 P56817 1/20 0.51
EGFR P00533 1/20 0.51
ALDH1A1 P00352 2/20 0.50
THRB P10828 1/20 0.50
DGAT1 O75907 1/20 0.49
LMNA P02545 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456870 0.86 NAMPT (0.64) RAB9ANPC1MAPTSMN1; SMN2L3MBTL1
SCHEMBL5458300 0.86 MAPT (0.61) RAB9AMAPTSMN1; SMN2TP53CA12
SCHEMBL3307714 0.84 RAB9A (0.60) RAB9ANPC1MAPTSMN1; SMN2L3MBTL1
SCHEMBL3307712 0.84 RAB9A (0.60) RAB9ANPC1MAPTSMN1; SMN2L3MBTL1
SCHEMBL5458347 0.83 RAB9A (0.61) RAB9ANPC1MAPTSMN1; SMN2L3MBTL1
SCHEMBL5455925 0.83 NPC1 (0.56) RAB9ANPC1MAPTSMN1; SMN2TP53
SCHEMBL5459164 0.83 RAB9A (0.48) RAB9ANPC1MAPTSMN1; SMN2TP53
SCHEMBL5465394 0.82 RAB9A (0.75) RAB9ANPC1MAPTSMN1; SMN2L3MBTL1
SCHEMBL5459980 0.81 GFER (0.62) RAB9ANPC1MAPTSMN1; SMN2L3MBTL1
SCHEMBL5459401 0.80 HSD17B10 (0.49) RAB9ANPC1MAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 RAB9A 1528/4885NPC1 1089/4885MAPT 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.